Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 10/30 04:00:00 pm
84.98 USD   +5.34%
11:43aGLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
10:22aWall St slumps as tech stocks slide, COVID cases jump
RE
09:51aABBVIE : Correction to AbbVie Earnings Article
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
83.92(c) 82.71(c) 80.49(c) 80.67(c) 85.1(c) Last
7 986 251 6 705 599 11 480 182 8 876 696 18 065 087 Volume
-0.50% -1.44% -2.68% +0.22% +5.49% Change
More quotes
Financials (USD)
Sales 2020 45 519 M - -
Net income 2020 - - -
Net Debt 2020 74 016 M - -
P/E ratio 2020 21,8x
Yield 2020 5,80%
Sales 2021 53 260 M - -
Net income 2021 16 914  - -
Net Debt 2021 63 003 M - -
P/E ratio 2021 9,58x
Yield 2021 6,04%
Capitalization 142 B 142 B -
EV / Sales 2020 4,75x
EV / Sales 2021 3,86x
Nbr of Employees 47 000
Free-Float 98,5%
More Financials
Company
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Sales are distributed geographically as follows: the United States (71.9%), Japan (3.7%), Germany... 
Sector
Pharmaceuticals
Calendar
10/30Earnings Release
More about the company
Notations Surperformance© of AbbVie Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ABBVIE INC.
11:43aGLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
10:22aWall St slumps as tech stocks slide, COVID cases jump
RE
09:51aABBVIE : Correction to AbbVie Earnings Article
DJ
08:23aABBVIE : Logs 3Q Sales Growth on Higher Immunology, Oncology Results
DJ
07:57aABBVIE : 3Q Earnings Snapshot
AQ
07:54aABBVIE INC. : Results of Operations and Financial Condition, Financial Statement..
AQ
10/29ABBVIE : Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results..
AQ
10/29ABBVIE : Highlights Innovative Research for People with Rheumatic Diseases with ..
AQ
10/29ABBVIE : to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ ..
PR
10/28ABBVIE : Allergan Presbyopia Treatment Hits Main Endpoint in Phase 3 Studies
DJ
10/28ABBVIE : Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results..
PR
10/28Molecular Partners jumps after Novartis deal for potential COVID-19 drugs
RE
10/28Molecular Partners jumps after Novartis deal for potential COVID-19 drugs
RE
10/27ABBVIE INC. : quaterly earnings release
10/19ABBVIE : Seeks U.S., European OK of Rinvoq in Eczema
DJ
More news
News in other languages on ABBVIE INC.
04:04aLes GAFA ne guérissent pas tous les maux
03:26aEN DIRECT DES MARCHES : Air France KLM, Amundi, Casino, Total, Safran, Volvo, La..
10/27ABBVIE INC. : publication des résultats trimestriels
10/27ABBVIE INC. : Veröffentlichung des Quartalsergebnisses
10/18ROCHE : FDA-Zulassung für Venclexta-Kombinationen bei myeloischer Leukämie
More news
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 109,25 $
Last Close Price 85,10 $
Spread / Highest target 49,2%
Spread / Average Target 28,4%
Spread / Lowest Target 12,8%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.-8.89%142 369
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518